DB-1310 by Duality Biologics (Shanghai) for Solid Tumor: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Solid Tumor.

Healthcare Security & Privacy Challenges of ChatGPT, AI Tools

Jon Moore, MS, JD, HCISPP, Chief Risk Officer and SVP of Clearwater Recent advances in Generative AI Large Language Models, such as ChatGPT, have been

August 21, 2023

Trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England

Researchers assessed mortality trends in the leading cancers from 2002 to 2019 across 314 districts in England using high-resolution spatiotemporal analysis.

December 14, 2023

Meet the people deciding how to spend $50 billion in opioid settlement cash

As more than $50 billion makes its way to state and local governments to compensate for the opioid epidemic, people with high hopes for the

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.